-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] The listing of new stocks has always attracted the attention of the indust.
This week, a total of 11 new stocks were listed, including State Cable Testing, Youji, Sany Heavy Energy, e.
, and next week, there will be 6 new stocks list.
Only new shares were listed, including 2 new pharmaceutical shares, namely Purui Ophthalmology and Fuyuan Medici.
Specifically, Purui Ophthalmology plans to subscribe on June 20 and issue a total of 37,404,762 shares, of which 166 million shares are issued online, with a subscription limit of 10,500 shar.
According to the prospectus, Purui Ophthalmology is a professional chain ophthalmic medical institution integrating outpatient, clinical, medical and medical technology developme.
Its main business is to provide professional ophthalmic medical services to patients with ophthalmic diseas.
The company's products or services mainly include refractive projects, cataract projects, medical optometry projects and comprehensive eye disease projects, including refractive surgery, medical optometry, cataract, glaucoma, strabismus and amblyopia and pediatric eye diseases, fundus diseases, and ophthalmolo.
And lacrimal duct, corneal disease and other ophthalmic general diagnosis and treatment projec.
The company adopts the "direct chain" business model, and provides ophthalmic medical services for eye disease patients through its affiliated chain hospita.
At present, Purui Ophthalmology has a total of 23 professional eye hospitals and 3 eye clinics in many municipalities and provincial capitals across the country, as well as professional eye disease research institutes, providing technical support for the company to carry out eye medical servic.
Financial data shows that the net profits attributable to owners of the parent company from 2019 to 2021 are 40548 million yuan, 109 million yuan and 98893 million yuan respective.
The performance in the first half of 2022 will still decli.
The company expects that the net profit attributable to 19 million yuan to 41 million yuan from January to June 2022, a year-on-year decrease of 325% to 79After deducting the issuance costs, the company will invest in: the new project of Changchun Purui Eye Hospital, the reconstruction project of Harbin Purui Eye Hospital, the information management construction project, and the supplementary working capit.
It is planned to invest 286 million yuan of raised fun.
Fuyuan Pharmaceutical plans to subscribe on June 21, issuing a total of 120 million shares, 36 million shares online, with a subscription limit of 36,000 shar.
According to the prospectus, the company is mainly engaged in the research and development, production and sales of pharmaceutical preparations and medical devic.
The company's product categories are rich, and its pharmaceutical preparations currently mainly cover cardiovascular system, chronic kidney disease, skin disease, digestive system, diabetes, mental nervous system, gynecology and other product segmen.
It has losartan potassi.
Hydrochlorothiazide Tablets, Olmesartan Medoxomil Tablets, Telmisartan Tablets, Trimetazidine Hydrochloride Tablets, Atorvastatin Calcium Tablets, Compound Alpha-Keto Acid Tablets, Hacinide Solution, Pinaverium Bromide Tablets, Kaisailu , repaglinide tablets, gliclazide sustained-release tablets, acarbose tablets, paroxetine hydrochloride tablets, venlafaxine hydrochloride sustained-release capsules, progesterone soft capsules and many other major products; the company's medical device business includes Humidification and oxygen absorption devices are the main products, and the main products include disposable oxygen absorption tub.
In 2019, 2020 and 2021, the company's net profit attributable to shareholders of the issuer after deducting non-recurring gains and losses was 200 million yuan, 250 million yuan and 305 million yuan respective.
In addition, entering 2022, the company's operating performance from January to March will maintain a growth trend, achieving operating income of 74,800 yuan, an increase of 243% over the same period of the previous year; net profit of 89939 million yuan, an increase of 483% over the same period of the previous ye.
In addition, the company's public offering to raise funds for investment projects closely focus on the company's main business, mainly in the field of production research and development, is a strategic arrangement made by the company according to the future development pl.
Click to enter the exhibition page
This week, a total of 11 new stocks were listed, including State Cable Testing, Youji, Sany Heavy Energy, e.
, and next week, there will be 6 new stocks list.
Only new shares were listed, including 2 new pharmaceutical shares, namely Purui Ophthalmology and Fuyuan Medici.
Specifically, Purui Ophthalmology plans to subscribe on June 20 and issue a total of 37,404,762 shares, of which 166 million shares are issued online, with a subscription limit of 10,500 shar.
According to the prospectus, Purui Ophthalmology is a professional chain ophthalmic medical institution integrating outpatient, clinical, medical and medical technology developme.
Its main business is to provide professional ophthalmic medical services to patients with ophthalmic diseas.
The company's products or services mainly include refractive projects, cataract projects, medical optometry projects and comprehensive eye disease projects, including refractive surgery, medical optometry, cataract, glaucoma, strabismus and amblyopia and pediatric eye diseases, fundus diseases, and ophthalmolo.
And lacrimal duct, corneal disease and other ophthalmic general diagnosis and treatment projec.
The company adopts the "direct chain" business model, and provides ophthalmic medical services for eye disease patients through its affiliated chain hospita.
At present, Purui Ophthalmology has a total of 23 professional eye hospitals and 3 eye clinics in many municipalities and provincial capitals across the country, as well as professional eye disease research institutes, providing technical support for the company to carry out eye medical servic.
Financial data shows that the net profits attributable to owners of the parent company from 2019 to 2021 are 40548 million yuan, 109 million yuan and 98893 million yuan respective.
The performance in the first half of 2022 will still decli.
The company expects that the net profit attributable to 19 million yuan to 41 million yuan from January to June 2022, a year-on-year decrease of 325% to 79After deducting the issuance costs, the company will invest in: the new project of Changchun Purui Eye Hospital, the reconstruction project of Harbin Purui Eye Hospital, the information management construction project, and the supplementary working capit.
It is planned to invest 286 million yuan of raised fun.
Fuyuan Pharmaceutical plans to subscribe on June 21, issuing a total of 120 million shares, 36 million shares online, with a subscription limit of 36,000 shar.
According to the prospectus, the company is mainly engaged in the research and development, production and sales of pharmaceutical preparations and medical devic.
The company's product categories are rich, and its pharmaceutical preparations currently mainly cover cardiovascular system, chronic kidney disease, skin disease, digestive system, diabetes, mental nervous system, gynecology and other product segmen.
It has losartan potassi.
Hydrochlorothiazide Tablets, Olmesartan Medoxomil Tablets, Telmisartan Tablets, Trimetazidine Hydrochloride Tablets, Atorvastatin Calcium Tablets, Compound Alpha-Keto Acid Tablets, Hacinide Solution, Pinaverium Bromide Tablets, Kaisailu , repaglinide tablets, gliclazide sustained-release tablets, acarbose tablets, paroxetine hydrochloride tablets, venlafaxine hydrochloride sustained-release capsules, progesterone soft capsules and many other major products; the company's medical device business includes Humidification and oxygen absorption devices are the main products, and the main products include disposable oxygen absorption tub.
In 2019, 2020 and 2021, the company's net profit attributable to shareholders of the issuer after deducting non-recurring gains and losses was 200 million yuan, 250 million yuan and 305 million yuan respective.
In addition, entering 2022, the company's operating performance from January to March will maintain a growth trend, achieving operating income of 74,800 yuan, an increase of 243% over the same period of the previous year; net profit of 89939 million yuan, an increase of 483% over the same period of the previous ye.
In addition, the company's public offering to raise funds for investment projects closely focus on the company's main business, mainly in the field of production research and development, is a strategic arrangement made by the company according to the future development pl.
Click to enter the exhibition page
